Nieuws en video's - DYNAVAX TECHNOLOGIES - Engels - Pagina 3

Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 PR Newswire EMERYVILLE, Calif., Feb. 9, 2023 EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 , after the U.S. financial markets close....

Dynavax Announces Uplisting to the Nasdaq Global Select Market PR Newswire EMERYVILLE, Calif., Jan. 31, 2023 EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023 , its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue...

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results PR Newswire EMERYVILLE, Calif., Jan. 9, 2023 Preliminary full year 2022 HEPLISAV-B ® vaccine Net Product Revenue of approximately $126 million , representing 104% growth compared to 2021 Preliminary full year CpG 1018 ® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and investments of...

Dynavax to Present at Two Upcoming Investor Conferences PR Newswire EMERYVILLE, Calif., Nov. 9, 2022 EMERYVILLE, Calif. , Nov. 9, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, and Kelly MacDonald , Chief Financial Officer, will participate in two upcoming investor conferences: Guggenheim Healthcare Talks | 4th Annual...

Dynavax Reports Third Quarter 2022 Financial Results PR Newswire EMERYVILLE, Calif., Nov. 3, 2022 Q3 2022 total revenue of $167.7 million , up 55% from $108.3 million for Q3 2021 HEPLISAV-B ® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant net product revenue of $126.3 million , up 50% from $84.3 million for Q3 2021 Reiterates guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million On track...

Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022 PR Newswire EMERYVILLE, Calif., Oct. 20, 2022 EMERYVILLE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022 , after the U.S. financial markets close. Dynavax will host a conference call and live...

Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine PR Newswire EMERYVILLE, Calif., Sept. 12, 2022 EMERYVILLE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, in collaboration with the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear...

Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire EMERYVILLE, Calif., Sept. 8, 2022 EMERYVILLE, Calif. , Sept. 8, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference,...

Thinking about buying stock in AN2 Therapeutics, AMTD IDEA Group, Dynavax Technologies, Yelp, or Honest Company? PR Newswire NEW YORK, Aug. 5, 2022 NEW YORK , Aug. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANTX, AMTD, DVAX, YELP, and HNST. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ANTX:...

Dynavax Reports Second Quarter 2022 Financial Results PR Newswire EMERYVILLE, Calif., Aug. 4, 2022 Q2 2022 total revenue of $256.5 million , up 386% from $52.8 million for Q2 2021 HEPLISAV-B ® vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 CpG 1018 ® adjuvant net product revenue of $222.6 million , up 471% from $39.0 million for Q2 2021 On track for second consecutive year of profitability Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE,...

Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022 PR Newswire EMERYVILLE, Calif., July 21, 2022 EMERYVILLE, Calif. , July 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter financial results on Thursday, August 4, 2022 , after the U.S. financial markets close. Dynavax will host a conference call and live...

Dynavax to Present at the H.C. Wainwright Global Investment Conference PR Newswire EMERYVILLE, Calif., May 16, 2022 EMERYVILLE, Calif. , May 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022 . The on demand presentation will...

Dynavax Reports First Quarter 2022 Financial Results PR Newswire EMERYVILLE, Calif., May 5, 2022 First quarter 2022 total revenue of $114.0 million , up 37% from $83.3 million for Q1 2021 HEPLISAV-B ® vaccine net product revenue of $20.8 million , up 151% from $8.3 million for Q1 2021 CpG 1018® adjuvant net product revenue of $91.5 million , up 23% from $74.6 million for Q1 2021 Guidance reiterated for 2022 CpG 1018 revenue, operating expenses, and other costs On track for a second consecutive...

Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022 PR Newswire EMERYVILLE, Calif., April 21, 2022 EMERYVILLE, Calif. , April 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report first quarter 2022 financial results on Thursday, May 5, 2022 , after the U.S. financial markets close. Dynavax will host a conference...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., April 5, 2022 EMERYVILLE, Calif. , April 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 28,250 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on April 1, 2022 ,...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., March 8, 2022 EMERYVILLE, Calif. , March 8, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 33,250 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 48,250 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., March 3, 2022 EMERYVILLE, Calif. , March 3, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 1, 2022 ,...

Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance - Record 2021 total revenue of $439 million, up from $47 million for 2020 -- Record full year HEPLISAV-B®net product revenue of $62 million -- Record full year CpG 1018® adjuvant net product revenue of $375 million, meeting previously...

Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022 PR Newswire EMERYVILLE, Calif., Feb. 16, 2022 EMERYVILLE, Calif. , Feb. 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022 , after the U.S. financial markets...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Feb. 2, 2022 EMERYVILLE, Calif. , Feb. 2, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 105,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 73,250 shares of Dynavax common stock as inducements to 11 newly-hired employees in connection...